Ken Garber
#154,150
Most Influential Person Now
Ken Garber's AcademicInfluence.com Rankings
Download Badge
Biology
Ken Garber's Degrees
- Bachelors Biology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Ken Garber Influential?
(Suggest an Edit or Addition)Ken Garber's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- China approves world's first oncolytic virus therapy for cancer treatment. (2006) (460)
- Energy Deregulation: Licensing Tumors to Grow (2006) (272)
- Energy boost: the Warburg effect returns in a new theory of cancer. (2004) (209)
- RIKEN suspends first clinical trial involving induced pluripotent stem cells (2015) (191)
- From human to mouse and back: 'tumorgraft' models surge in popularity. (2009) (140)
- Autism's Cause May Reside in Abnormalities at the Synapse (2007) (112)
- Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. (2008) (112)
- Driving T-cell immunotherapy to solid tumors (2018) (109)
- Bispecific antibodies rise again (2014) (103)
- Alnylam launches era of RNAi drugs (2018) (102)
- HDAC inhibitors overcome first hurdle (2007) (97)
- Rapamycin's resurrection: a new way to target the cancer cell cycle. (2001) (87)
- Stromal depletion goes on trial in pancreatic cancer. (2010) (69)
- Drugging the Wnt pathway: problems and progress. (2009) (66)
- The second wave in kinase cancer drugs (2006) (63)
- Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis (2011) (60)
- Gene Expression Tests Foretell Breast Cancer's Future (2004) (59)
- Notch emerges as new cancer drug target. (2007) (56)
- Angiogenesis inhibitors suffer new setback (2002) (56)
- Improved Paclitaxel formulation hints at new chemotherapy approach. (2004) (55)
- A new cancer immunotherapy suffers a setback. (2018) (54)
- First results for agents targeting cancer-related inflammation. (2009) (53)
- No longer going to waste (2016) (52)
- Drugging the gut microbiome (2015) (50)
- Peptide leads new class of chronic pain drugs (2005) (48)
- The PROTAC gold rush (2021) (48)
- Anti-IL-17 mAbs herald new options in psoriasis (2012) (47)
- Genentech's Alzheimer's antibody trial to study disease prevention (2012) (47)
- MET inhibitors start on road to recovery (2014) (45)
- IGF-1: old growth factor shines as new drug target. (2005) (44)
- New apoptosis drugs face critical test (2005) (43)
- BIOMEDICINE. Targeting copper to treat breast cancer. (2015) (43)
- Realistic rodents? Debate grows over new mouse models of cancer. (2006) (43)
- Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia. (2010) (40)
- Biotech industry faces new bottleneck (2001) (39)
- Alnylam terminates revusiran program, stock plunges (2016) (37)
- Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market (2013) (37)
- Cancer anabolic metabolism inhibitors move into clinic (2016) (35)
- PARP inhibitors bounce back (2013) (35)
- Debate rages over proteomic patterns. (2004) (34)
- ALK, lung cancer, and personalized therapy: portent of the future? (2010) (33)
- Cancer research. Melanoma drug vindicates targeted approach. (2009) (33)
- Fixing the front end (2008) (33)
- Inducing indigestion: companies embrace autophagy inhibitors. (2011) (32)
- Promising early results for immunotherapy-antiangiogenesis combination. (2014) (32)
- Stroke treatment—light at the end of the tunnel? (2007) (31)
- Companies waver in efforts to target transforming growth factor beta in cancer. (2009) (31)
- Parkinson's disease and cancer: the unexplored connection. (2010) (29)
- Beyond ipilimumab: new approaches target the immunological synapse. (2011) (29)
- Fate of novel painkiller mAbs hangs in balance (2011) (29)
- New checkpoint blockers begin human trials. (2005) (28)
- Hedgehog drugs begin to show results. (2008) (28)
- Missing the target: ubiquitin ligase drugs stall. (2005) (28)
- Targeting mTOR: something old, something new. (2009) (28)
- The Elusive ALS Genes (2008) (28)
- Biochemistry: A radical treatment (2012) (26)
- Hepatitis C: move over interferon (2011) (26)
- Autophagy. Explaining exercise. (2012) (25)
- Inducing translation (2013) (25)
- Immunology: A tolerant approach (2014) (24)
- Psoriasis: from bed to bench and back (2011) (24)
- Taking Garbage In, Tossing Cancer Out? (2002) (24)
- Patently absurd? (2006) (24)
- The cancer drug that almost wasn't. (2014) (24)
- New drugs target hypoxia response in tumors. (2005) (23)
- Personal mouse colonies give hope for pancreatic cancer patients. (2007) (23)
- A β-lactamase inhibitor revival provides new hope for old antibiotics (2015) (23)
- Immune agonist antibodies face critical test (2019) (22)
- Of Ephs and ephrins: companies target guidance molecules in cancer. (2010) (22)
- Worth the RISC? (2017) (22)
- Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up (2019) (22)
- Cancer's copper connections. (2015) (21)
- Tissue-agnostic cancer drug pipeline grows, despite doubts (2018) (20)
- First microbiome-based drug clears phase III, in clinical trial turnaround (2020) (20)
- Aspirin for cancer chemoprevention: still a headache? (2004) (20)
- A mid-life crisis for aging theory (2008) (19)
- Targeting mitochondria emerges as therapeutic strategy. (2005) (19)
- In a major shift, cancer drugs go 'tissue-agnostic'. (2017) (19)
- Lymphoma rate rise continues to baffle researchers. (2001) (19)
- Big win possible for Ionis/Biogen antisense drug in muscular atrophy (2016) (18)
- Kinase inhibitors overachieve in CLL (2014) (18)
- Purchase of Aton spotlights HDAC inhibitors (2004) (18)
- Genetics: Deep exploration (2012) (18)
- Synthetic lethality: killing cancer with cancer. (2002) (18)
- Two pioneering osteoporosis drugs finally approach approval (2016) (17)
- Cancer stem cell pipeline flounders (2018) (17)
- Divide and conquer: new generation of drugs targets mitosis. (2005) (17)
- γδ T cells bring unconventional cancer-targeting to the clinic — again (2020) (17)
- Oncology's energetic pipeline (2010) (17)
- rFactor VIII deficit questioned (2000) (16)
- Breaking the silence: the rise of epigenetic therapy. (2002) (16)
- Trial offers early test case for personalized medicine. (2009) (16)
- Protein C may be sepsis solution (2000) (15)
- Rapamycin may prevent post-transplant lymphoma. (2001) (15)
- Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy (2017) (15)
- Momentum building for human epigenome project. (2006) (15)
- Tamoxifen pharmacogenetics moves closer to reality. (2005) (15)
- First FDA-approved beta-amyloid diagnostic hits the market (2012) (14)
- Predictive biomarkers for checkpoints, first tests approved (2015) (14)
- Why it hurts: researchers seek mechanisms of cancer pain. (2003) (14)
- Tyrosine kinase inhibitor research presses on despite halted clinical trial. (2000) (13)
- Hepatitis C: staying the course (2007) (13)
- Cancer research. Taking garbage in, tossing cancer out? (2002) (13)
- Human Cancer Genome Project moving forward despite some doubts in community. (2005) (13)
- Alnylam's RNAi therapy targets amyloid disease (2015) (12)
- Biotech in a blink (2010) (12)
- Coronavirus vaccine developers wary of errant antibodies (2020) (11)
- A tale of two cells: discovering the origin of prostate cancer. (2010) (11)
- New insights into oncogene addiction found. (2007) (11)
- Infections cast cloud over Novartis' MS therapy (2008) (11)
- Users fear that lymphoma drugs will disappear. (2007) (11)
- Ready or not: personal tumor profiling tests take off. (2011) (11)
- Biologics inch toward cholesterol-lowering market (2012) (11)
- Beyond the Nobel Prize: cell cycle research offers new view of cancer. (2001) (10)
- Researchers target unfolded protein response in cancerous tumor growth. (2006) (10)
- Melanoma combination therapies ward off tumor resistance (2013) (10)
- At the frontiers of lung fibrosis therapy (2013) (10)
- Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responses (2018) (10)
- Could less be more? Low-dose chemotherapy goes on trial. (2002) (10)
- The new liver epidemic (2019) (10)
- JAK2 inhibitors: not the next imatinib but researchers see other possibilities. (2009) (10)
- Industry 'road tests' new wave of immune checkpoints (2017) (10)
- Targeting vessel abnormalization in cancer. (2007) (9)
- Make or break for costimulatory blockers (2004) (9)
- Industry makes strides in melanoma (2010) (9)
- Small RNAs Reveal an Activating Side (2006) (8)
- Blood test may predict cancer immunotherapy benefit. (2018) (8)
- Nature Biotechnology’s academic spinouts of 2018 (2019) (7)
- Immunology's quiet upheaval (2009) (7)
- Natural killer cells blaze into immuno-oncology (2016) (7)
- No miR hype: microRNA's cancer role expands. (2006) (7)
- Epigenetics comes to RNA. (2019) (7)
- Genetics. Small RNAs reveal an activating side. (2006) (7)
- Big plans for small molecules: NIH launches chemical genomics initiative. (2003) (7)
- CELL BIOLOGY. Protein 'drops' may seed brain disease. (2015) (7)
- Silence of the genes: cancer epigenetics arrives. (2002) (6)
- At loose ends: telomere theories of aging and cancer begin to converge. (2012) (6)
- No added sugar: antibody makers find an upside to 'no fucose' (2018) (6)
- Adenosine checkpoint agent blazes a trail, joins immunotherapy roster (2017) (6)
- RAC Urges Changes to Retinoblastoma Plan (1999) (6)
- New gene discoveries may boost DNA stool testing for colorectal cancer. (2004) (6)
- Translational Institute Unites Unlikely Partners at Penn (2007) (6)
- New discoveries still abundant in monoclonal antibody research. (2000) (5)
- ODAC panel gives nod to Bexxar. (2003) (5)
- Controversial allocation rules for liver transplants (2002) (5)
- Histone-writer cancer drugs enter center stage (2020) (5)
- Ontario institute offers new model of cancer research. (2008) (5)
- Beyond sequencing: new diagnostic tests turn to pathways. (2011) (5)
- Evading immunity: new enzyme implicated in cancer. (2012) (5)
- Trial results boost circulating tumor cell field. (2004) (5)
- Hunt for improved monoclonals against coronavirus gathers pace (2021) (5)
- STI571 revolution: can the newer targeted drugs measure up? (2001) (5)
- Between disease and a dish (2014) (5)
- For Bexxar, FDA meeting offers long-awaited chance at approval. (2002) (4)
- Sugen falls as casualty of Pfizer–Pharmacia merger (2003) (4)
- Broad Patent Faces Narrow Odds in Court Battle (2006) (4)
- Erratum: Near-optimal probabilistic RNA-seq quantification (2016) (4)
- The clot stopper. (2006) (4)
- Better blocker: RNA interference dazzles research community. (2003) (4)
- Battle over generic taxol concludes, but controversy continues. (2002) (4)
- Running interference: pace picks up on synthetic lethality research. (2004) (4)
- Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure. (2003) (4)
- A promising new cancer drug has hit a major setback, raising questions about whether the field is moving too fast (2018) (4)
- First metabolic oncology inhibitor gets FDA green light, with record price tag (2017) (4)
- Principia Biopharma (2013) (3)
- Decision on NFκB Patent Could Have Broad Implications for Biotech (2006) (3)
- Year of the Cat--in More Ways Than One (1998) (3)
- Lymphoma market turf war imminent, pending Bexxar approval (2003) (3)
- First-in-class biologic to enter rheumatoid arthritis fray (2005) (3)
- Newsmaker: Lycera (2011) (3)
- The next wave of the genomics business (2000) (3)
- Neurodegeneration. Potential Alzheimer's drug spurs protein recycling. (2014) (3)
- Troubled big pharma turns away from biotech (2002) (3)
- Genetic discoveries propagate new epigenetic drugs. (2012) (3)
- RAC nixes plan to treat retinoblastoma. (1999) (3)
- Melanoma antibody approved (2011) (3)
- On the eve of protein destruction: ubiquitin research begins to pay off. (2002) (2)
- Erratum: The long view on sequencing (2018) (2)
- US NHGRI launches chemical attack on drug development gap (2003) (2)
- Companies Waver in Efforts To Target Transforming Growth Factor (cid:1) in Cancer (2009) (2)
- Science careers. Translational institute unites unlikely partners at Penn. (2007) (2)
- Gene mutation revelation points to new target for myeloma treatment, studies say. (2007) (2)
- Amyloid disease drug approved (2012) (2)
- Nature Biotechnology’s academic spinouts 2021 (2022) (1)
- mRNA pioneers refocus on therapeutics (2022) (1)
- Oncologists push beyond new lung cancer genomic testing guidelines. (2015) (1)
- New method found to trigger cancer cell suicide. (2006) (1)
- Orna Therapeutics: circular logic. (2022) (1)
- Nature Biotechnology's academic spinouts of 2017 (2018) (1)
- Erratum: No longer going to waste (2016) (1)
- Erratum: Fate of novel painkiller mAbs hangs in balance (2012) (1)
- Bristol-Myers Squibb locks into novel autoimmune strategy (2016) (1)
- Ariad's NFκB patent claims shot down on appeal (2009) (1)
- Proteostasis Therapeutics (2009) (1)
- Publisher Correction: γδ T cells bring unconventional cancer-targeting to the clinic — again (2020) (1)
- Synthekine: beyond cytokines. (2021) (1)
- Neuroscience. All eyes on RNA. (2012) (1)
- Varietal trials with flax in Schleswig-Holstein with special reference to quality. (1960) (1)
- Mutation-counting blood test could predict if cutting-edge immunotherapies can beat a cancer (2018) (1)
- The new liver epidemic (2019) (0)
- “Troubled big pharma turns away from biotech” (2002) (0)
- Delix Therapeutics : psychedelics without the trip. (2022) (0)
- Tech transfer pays off (2002) (0)
- Publisher Correction: γδ T cells bring unconventional cancer-targeting to the clinic — again (2020) (0)
- NIH licensing performance under par. (2004) (0)
- Ariad's NF-κB blow (2010) (0)
- Mission Therapeutics (2012) (0)
- Correction: Corrigendum: Editors' Pick: Orphazyme (2013) (0)
- Erratum: Nature Biotechnology's academic spinouts of 2017 (2018) (0)
- Van Andel Institute brings cancer research to the heartland. (2001) (0)
- Erratum: Drugging the gut microbiome (2017) (0)
- Immune agonist antibodies face critical test (2019) (0)
- Erratum: Make or break for costimulatory blockers (2004) (0)
- First Rounders: Nina Tandon (2019) (0)
- Hunt for improved monoclonals against coronavirus gathers pace (2021) (0)
- Hidden layer of gene control influences everything from cancer to memory (2019) (0)
- The lysosomal degraders. (2022) (0)
- Publisher Correction: Histone-writer cancer drugs enter center stage (2020) (0)
- Erratum: Make or break for costimulatory blockers (2004) (0)
- Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy (2017) (0)
- Tumor macrophage target fuels $1.7-billion deal (2015) (0)
- Erratum: Biotech in a blink (2010) (0)
- Nature Biotechnology’s academic spinouts 2020 (2021) (0)
This paper list is powered by the following services:
